Physician profile
Norberto Schechtmann
NPI 1457336984
$11,384.27
in general payments reported to CMS, 2019-2025
32 companies · $1,383 in 2025
The $1,383 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,775 · 2020: $805 · 2021: $3,822 · 2022: $1,772 · 2023: $130 · 2024: $698 · 2025: $1,383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,210.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,607.48 | 2021-2025 | Protege Rx, Linq II |
| Penumbra, INC. | $1,911.98 | 2019-2022 | |
| Abbott Laboratories | $1,798.95 | 2019-2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Shockwave Medical, INC | $717.50 | 2025 | |
| Janssen Pharmaceuticals, INC | $700.89 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $681.66 | 2020-2025 | Lifevest |
| Amgen INC. | $454.91 | 2019-2024 | Repatha |
| Abiomed | $371.84 | 2019-2025 | |
| Boston Scientific Corporation | $293.18 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $248.75 | 2019-2025 | Eliquis, Camzyos |
| Medtronic Vascular, INC. | $214.32 | 2019 | |
| Pfizer INC. | $193.66 | 2019-2020 | |
| Edwards Lifesciences Corporation | $154.75 | 2019-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Cook Medical LLC | $120.88 | 2021 | |
| Cvrx, INC. | $118.35 | 2025 | Barostim Neo System |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $105.58 | 2025 | Inspire |
| Sanofi-Aventis U.S. LLC | $94.80 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $86.02 | 2019-2024 | |
| Biotronik INC. | $62.45 | 2023 | Sentus, Acticor 7 Vr-T Dx |
| Cardiovascular Systems INC. | $60.22 | 2020 | |
| Azurity Pharmaceuticals, INC. | $50.23 | 2023-2024 | Edarbyclor, Edarbi |
| Philips North America LLC | $49.01 | 2020 | |
| Esperion Therapeutics, INC. | $42.90 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $41.18 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.89 | 2019 | |
| Amarin Pharma, INC. | $36.04 | 2019 | |
| Merck Sharp & Dohme LLC | $33.63 | 2024 | Verquvo |
| Gilead Sciences, INC. | $29.53 | 2019 | |
| Impulse Dynamics (USA) INC. | $19.48 | 2023 | Optimizer |
| Irhythm Technologies, INC. | $17.01 | 2019 | |
| Biosense Webster, INC. | $15.18 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $15.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norberto Schechtmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.